At the last check on Friday, Takeda Pharmaceutical Company Limited’s (NYSE:TAK) stock was up $0.05, moving up 0.39 percent to $14.31. The average number of shares traded per day over the past five days has been 2,875,776 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.29 fall in that time frame. In the last twenty days, the average volume was 2,341,854, while in the previous 50 days, it was 2,493,992.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, TAK stock retreated -3.39%. Shares of the company fell to $13.92 on 05/12/22, the lowest level in the past month. A 52-week high of $17.56 was reached on 02/18/22 after having rallying from a 52-week low of $13.17. Since the beginning of this year, TAK’s stock price has risen by 4.62% or $0.72, and marked a new high 16 times. However, the stock has declined by -18.48% since its 52-week high.
Right now, Takeda Pharmaceutical Company Limited (TAK) has a P/E ratio of about 13.33. The stock’s beta is 0.76. Besides these, the trailing price-to-sales (P/S) ratio of 1.68, the price-to-book (PB) ratio of 1.09, and the price-to-cash flow ratio of 7.84 may also be considered.
In the three months ended September 29, Takeda Pharmaceutical Company Limited’s quick ratio stood at 0.90, while its current ratio was 1.40, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.79, and the total debt-to-equity ratio was 0.82. On the profitability front, the trailing twelve-month gross margin is 69.70% percent. In the year ended September 29, EBITDA margin amounted to 31.50%, whereas operating margins totaled 17.70%. Based on annual data, TAK earned $39.41 billion in gross profit and brought in $30.06 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 5.30%. Return on equity (ROE) for the past 12 months was 8.30%.
In Takeda Pharmaceutical Company Limited’s quarter-end financial report for September 29, it reported total debt of $512.16 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Takeda Pharmaceutical Company Limited to report $0.99 quarterly earnings, the actual figure was $0.01 per share, beating the consensus estimate by -99.00%. During the quarter, the company generated $2.24 billion in EBITDA. The liabilities of Takeda Pharmaceutical Company Limited were 64.83 billion at the end of its most recent quarter ended September 29, and its total debt was $4.35 trillion.
This quick technical analysis looks at Takeda Pharmaceutical Company Limited’s (TAK) price momentum. With a historical volatility rate of 32.23%, the RSI 9-day stood at 47.06% on 12 May.
With respect to its five-day moving average, the current Takeda Pharmaceutical Company Limited price is down by -1.98% percent or -$0.29. At present, TAK shares trade -3.76% below its 20-day simple moving average and +3.24% percent above its 100-day simple moving average. However, the stock is currently trading approximately -4.52% below its SMA50 and -15.24% below its SMA200.
Stochastic coefficient K was 30.95% and Stochastic coefficient D was 25.43%, while ATR was 0.28. Given the Stochastic reading of 51.19% for the 14-day period, the RSI (14) reading has been calculated as 46.73%. As of today, the MACD Oscillator reading stands at -0.24, while the 14-day reading stands at -0.26.
Takeda Pharmaceutical Company Limited downgraded its rating on Takeda Pharmaceutical Company Limited (NYSE: TAK) to an Equal-weight in a note to investors on October 07, 2021. The analysts firm previously had an Overweight rating on the stock.Takeda Pharmaceutical Company Limited (TAK) has been rated Overweight by analysts. According to 0 brokerage firms, TAK is a sell, and 8 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 1 analyst rate Takeda Pharmaceutical Company Limited stock as buy, with 6 recommending it as overweight.
With a median target price of $15.96, the current consensus forecast for the stock is $13.05 – $25.37. Based on these forecasts, analysts predict Takeda Pharmaceutical Company Limited (TAK) will achieve an average price target of $16.75.